PTC Therapeutics (PTCT) Director Michael Schmertzler Sells Shares

What Happened

• Michael Schmertzler, a director of PTC Therapeutics (PTCT), sold a total of 20,000 shares in open-market transactions on September 9–10, 2026, generating approximately $1,351,803 in proceeds. The sales consisted of: 9,428 shares at $67.79 (≈ $639,124), 572 shares at a weighted average $68.67 (≈ $39,279), and 10,000 shares at $67.34 (≈ $673,400). These were outright sales (code S) rather than purchases or option exercises.

Key Details

• Transaction dates and prices:
  • 2026-09-09: 9,428 shares @ $67.79 (≈ $639,124)
  • 2026-09-09: 572 shares @ weighted avg $68.67 (prices ranged $67.54–$68.52) (≈ $39,279)
  • 2026-09-10: 10,000 shares @ $67.34 (≈ $673,400) (weighted trades ranged $66.84–$67.66)
• Total shares sold: 20,000; total proceeds: ≈ $1,351,803.
• Shares owned after transaction: Not specified in the provided excerpt — see the full Form 4 for post-transaction holdings.
• Notable footnotes:
  • One or more sales were effected pursuant to a written Rule 10b5-1 trading plan adopted by Section Six Partners, L.P. (the Reporting Person is a general and limited partner) on May 14, 2026.
  • Several sales were executed in multiple trades; the filing provides weighted-average prices and price ranges and offers to provide per-trade breakdowns on request (per footnotes).
  • The Reporting Person disclaims beneficial ownership of shares held by Section Six Partners, L.P., except to the extent of his pecuniary interest.
• Timeliness: Report filed Sept 11, 2026 (Period of Report Sept 9, 2026). This filing date appears timely for the reported trade dates.

Context

• These were open-market sales and at least some were carried out under a pre-arranged 10b5-1 plan, which typically indicates the sales were scheduled in advance and should not be read on their own as a new signal of management sentiment. Sales by directors can be routine (diversification, tax planning, or plan-driven) and do not necessarily reflect a change in view on company prospects. For full context, check the complete Form 4 for post-sale holdings and any related filings.